'Exciting Era' Underway

Article

San Francisco -- Patients with moderate to severe psoriasis can receive efalizumab (Anti-CD11a) continually with no increased toxicity for approximately one year, an ongoing open-label trial shows.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.